July 2025 in “Journal of Investigative Dermatology” This study found that high-dose UVA-1 therapy appeared to improve both patient-reported outcomes and objective clinical measures in patients with morphea and systemic sclerosis, supporting its potential efficacy for treating scleroderma.
179 citations
,
October 2018 in “American Journal of Clinical Dermatology” This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.
22 citations
,
March 2017 in “Journal of the Formosan Medical Association” This report presents the Taiwanese Dermatological Association's 2016 consensus on defining and managing skin toxicities from EGFR-TKI treatments, providing comprehensive guidelines for clinicians in Taiwan.
April 2023 in “Journal of Investigative Dermatology” This study reports that CD200R expression is significantly reduced in a mouse model of scarring alopecia, suggesting a potential role for this pathway in immune regulation and hair follicle protection.
October 2021 in “Journal of Investigative Dermatology” This study found no significant difference in SARS-CoV2 IgG seroconversion rates between patients with immune-mediated inflammatory diseases treated with targeted immune-modulating therapies and those on conventional systemic treatments.